Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial

Anti-cancer Drugs
Robert J AmatoJoan Hernandez-McClain

Abstract

Treatments for metastatic renal cell carcinoma (MRCC) are limited. RCCs frequently overexpress epithelial growth factor receptor and express c-Kit and platelet-derived growth factor receptor-beta. Combination of interferon with tyrosine kinase inhibitors of epithelial growth factor receptor [gefitinib (Iressa)] or c-Kit and platelet-derived growth factor receptor-beta [imatinib (Gleevec)] was evaluated for efficacy and safety. Patients with MRCC received 12-week cycles of interferon [3 million units (MU) subcutaneously thrice in week 1 and 6 MU thrice weekly thereafter] and either gefitinib (500 mg daily) or imatinib (600 mg daily). The gefitinib/imatinib dose was reduced as needed owing to toxicity. The primary endpoint was objective tumor response. Secondary endpoints were time to tumor progression, overall survival, and safety. Seventeen patients were enrolled. Most had clear cell [36% (6/17)] or papillary [36% (6/17)] tumors. Most (n=14) were treated on the gefitinib arm, including two patients who crossed over from the imatinib arm after experiencing disease progression. Objective tumor responses were evaluable in 14 patients (82%). Of these 14, partial responses occurred in three (21%), stable disease in seven (50%), and ...Continue Reading

References

Mar 1, 1977·The Journal of Urology·J E MontieD K Montague
Nov 1, 1989·The Journal of Urology·J S Horoszewicz, G P Murphy
Feb 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H B MussM S Mitchell
Oct 1, 1982·The American Journal of Surgical Pathology·S A FuhrmanC Limas
Jul 1, 1995·The Journal of Urology·D S SandockM I Resnick
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PyrhönenP L Kellokumpu-Lehtinen
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerE M Metz
Oct 19, 2001·Medicinal Research Reviews·P TraxlerJ Zimmermann
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Jul 19, 2003·Pharmacological Reviews·Michael W N Deininger, Brian J Druker
Oct 28, 2003·Investigational New Drugs·Beverly DruckerRobert Motzer
Feb 10, 2004·The Journal of Urology·Robert C FlaniganE David Crawford
Apr 23, 2004·Expert Opinion on Biological Therapy·David F McDermott, Michael B Atkins
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nancy A DawsonArif Hussain
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottMichael B Atkins
Aug 27, 2005·Clinical Pharmacokinetics·Bin PengHorst Schran
Dec 13, 2005·The New England Journal of Medicine·Herbert T Cohen, Francis J McGovern
Dec 29, 2005·Investigational New Drugs·Jacqueline VukyAndrew Jacobs
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Oct 10, 2006·Clinical Genitourinary Cancer·David F McDermottMichael B Atkins
Oct 19, 2006·Seminars in Oncology·David F McDermott, Michael B Atkins
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Apr 14, 2007·Cancer·Elias JabbourHagop M Kantarjian
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher W RyanUNKNOWN Southwest Oncology Group
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriBernard Escudier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.